JP Morgan Chase’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-211,078
| Closed | -$10.9M | – | 7361 |
|
|
2022
Q3 | $10.9M | Buy |
211,078
+155,018
| +277% | +$6.41M | ﹤0.01% | 2084 |
|
|
2022
Q2 | $1.39M | Sell |
56,060
-62,576
| -53% | -$1.38M | ﹤0.01% | 3841 |
|
|
2022
Q1 | $2.97M | Buy |
118,636
+74,101
| +166% | +$2.08M | ﹤0.01% | 3445 |
|
|
2021
Q4 | $1.62M | Sell |
44,535
-2,800
| -6% | -$98.3K | ﹤0.01% | 4017 |
|
|
2021
Q3 | $809K | Sell |
47,335
-596
| -1% | -$9.29K | ﹤0.01% | 4457 |
|
|
2021
Q2 | $642K | Buy |
47,931
+4,527
| +10% | +$112K | ﹤0.01% | 4546 |
|
|
2021
Q1 | $2.22M | Sell |
43,404
-285
| -0.7% | -$17.1K | ﹤0.01% | 3641 |
|
|
2020
Q4 | $2.71M | Buy |
43,689
+25,043
| +134% | +$1.43M | ﹤0.01% | 3267 |
|
|
2020
Q3 | $999K | Buy |
18,646
+3,440
| +23% | +$185K | ﹤0.01% | 3647 |
|
|
2020
Q2 | $875K | Buy |
15,206
+1,771
| +13% | +$96.4K | ﹤0.01% | 3590 |
|
|
2020
Q1 | $540K | Buy |
13,435
+330
| +3% | +$14K | ﹤0.01% | 3777 |
|
|
2019
Q4 | $518K | Sell |
13,105
-252
| -2% | -$4.42K | ﹤0.01% | 4218 |
|
|
2019
Q3 | $91K | Buy |
13,357
+2,166
| +19% | +$16.3K | ﹤0.01% | 4937 |
|
|
2019
Q2 | $100K | Buy |
11,191
+5,710
| +104% | +$66.1K | ﹤0.01% | 4939 |
|
|
2019
Q1 | $76K | Sell |
5,481
-257
| -4% | -$2.94K | ﹤0.01% | 4979 |
|
|
2018
Q4 | $63K | Buy |
5,738
+535
| +10% | +$5.64K | ﹤0.01% | 5001 |
|
|
2018
Q3 | $66K | Sell |
5,203
-192,027
| -97% | -$2.31M | ﹤0.01% | 5100 |
|
|
2018
Q2 | $2.6M | Buy |
197,230
+129,369
| +191% | +$1.55M | ﹤0.01% | 3200 |
|
|
2018
Q1 | $923K | Buy |
67,861
+49,944
| +279% | +$515K | ﹤0.01% | 3714 |
|
|
2017
Q4 | $107K | Buy |
+17,917
| New | +$123K | ﹤0.01% | 4642 |
|
|
2017
Q3 | – | Sell |
-11,097
| Closed | -$104K | – | 5270 |
|
|
2017
Q2 | $104K | Buy |
+11,097
| New | +$81.5K | ﹤0.01% | 4162 |
|
|
2017
Q1 | – | Sell |
-32,538
| Closed | -$241K | – | 5298 |
|
|
2016
Q4 | $241K | Buy |
+32,538
| New | +$234K | ﹤0.01% | 4095 |
|
|
2016
Q2 | – | Sell |
-86,218
| Closed | -$215K | – | 5038 |
|
|
2016
Q1 | $215K | Buy |
86,218
+3,951
| +5% | +$14.4K | ﹤0.01% | 3597 |
|
|
2015
Q4 | $666K | Sell |
82,267
-9,405
| -10% | -$66.6K | ﹤0.01% | 3287 |
|
|
2015
Q3 | $554K | Buy |
91,672
+450
| +0.5% | +$3.25K | ﹤0.01% | 3370 |
|
|
2015
Q2 | $751K | Sell |
91,222
-7,150
| -7% | -$56.8K | ﹤0.01% | 3412 |
|
|
2015
Q1 | $743K | Sell |
98,372
-4,475
| -4% | -$35K | ﹤0.01% | 3355 |
|
|
2014
Q4 | $703K | Sell |
102,847
-16,222
| -14% | -$85.8K | ﹤0.01% | 3527 |
|
|
2014
Q3 | $536K | Sell |
119,069
-1,639
| -1% | -$8.66K | ﹤0.01% | 3638 |
|
|
2014
Q2 | $706K | Sell |
120,708
-10,260
| -8% | -$57.6K | ﹤0.01% | 2996 |
|
|
2014
Q1 | $868K | Buy |
130,968
+20,475
| +19% | +$142K | ﹤0.01% | 2907 |
|
|
2013
Q4 | $640K | Sell |
110,493
-120,613
| -52% | -$622K | ﹤0.01% | 3355 |
|
|
2013
Q3 | $1.28M | Sell |
231,106
-231,878
| -50% | -$2.51M | ﹤0.01% | 3111 |
|
|
2013
Q2 | $6.55M | Buy |
+462,984
| New | +$6M | ﹤0.01% | 1942 |
|
Other funds holding CCXI
JP Morgan Chase's CCXI Position: Q4 2022 in Review
JP Morgan Chase sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 211,078 shares — an estimated $10.9M sold.
JP Morgan Chase first reported a position in CCXI in Q2 2013 and held it in 34 quarters. The position peaked at $10.9M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- JP Morgan Chase reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- JP Morgan Chase sold 211,078 ChemoCentryx, Inc. shares in Q4 2022, an estimated $10.9M.
- JP Morgan Chase first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 34 quarters.
- JP Morgan Chase's ChemoCentryx, Inc. position peaked at $10.9M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.